The prognostic value of hemoglobin change after initiating androgen‐deprivation therapy for newly diagnosed metastatic prostate cancer

The objective of this study was to characterize changes in hemoglobin (HGB) levels after the initiation of androgen‐deprivation therapy (ADT) in patients with previously untreated, metastatic prostate cancer who were enrolled in a large clinical trial.

[1]  H. Ford,et al.  DOMINANCE OF HIGH-PRODUCING INTERLEUKIN 6 AND LOW-PRODUCING INTERLEUKIN 10 AND INTERFERON γ ALLELES IN GLUCOSE-6-PHOSPHATE DEHYDROGENASE- DEFICIENT TRAUMA PATIENTS , 2005, Shock.

[2]  M. Benson,et al.  Acute hypoxia increases the aggressive characteristics and survival properties of prostate cancer cells , 2003, The Prostate.

[3]  Alexandra L Hanlon,et al.  Hypoxic prostate/muscle pO2 ratio predicts for biochemical failure in patients with prostate cancer: preliminary findings. , 2002, Urology.

[4]  D. Polsky,et al.  Altered N-myc Downstream-Regulated Gene 1 Protein Expression in African-American Compared with Caucasian Prostate Cancer Patients , 2004, Clinical Cancer Research.

[5]  Michael Höckel,et al.  Oxygenation gain factor: a novel parameter characterizing the association between hemoglobin level and the oxygenation status of breast cancers. , 2003, Cancer research.

[6]  A. Shabsigh,et al.  Castration induces acute vasoconstriction of blood vessels in the rat prostate concomitant with a reduction of prostatic nitric oxide synthase activity. , 1999, The Journal of urology.

[7]  H. Kung,et al.  Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK , 2004, Oncogene.

[8]  R. Ness,et al.  Differential distribution of allelic variants in cytokine genes among African Americans and White Americans. , 2004, American journal of epidemiology.

[9]  S. Krantz,et al.  Progress in understanding the pathogenesis of the anemia of chronic disease. , 1992, Blood.

[10]  R. Hoffman,et al.  Hematology: Basic Principles and Practice , 1995 .

[11]  Oliver Thews,et al.  Oxygenation Status of Gynecologic Tumors: What is the Optimal Hemoglobin Level? , 2002, Strahlentherapie und Onkologie.

[12]  W. Isaacs,et al.  Explaining racial differences in prostate cancer in the United States: Sociology or biology? , 2005, The Prostate.

[13]  E.,et al.  Progress in Understanding the Pathogenesis of the Anemia of Chronic Disease , 1992 .

[14]  I. Thompson,et al.  Prognostic value of anemia in newly diagnosed metastatic prostate cancer: a multivariate analysis of southwest oncology group study 8894. , 2004, The Journal of urology.

[15]  G. Murphy,et al.  The national cancer data base report on race, age, and region variations in prostate cancer treatment , 1997, Cancer.

[16]  A. Gao,et al.  Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  Kota Takahashi,et al.  The influence of androgen deprivation therapy on metabolism in patients with prostate cancer. , 2005, The Journal of clinical endocrinology and metabolism.

[18]  M. Malinow,et al.  Higher total homocysteine concentrations and lower folate concentrations in premenopausal black women than in premenopausal white women. , 1999, The American journal of clinical nutrition.

[19]  F. Dammacco,et al.  Recent Advances in Understanding the Pathogenesis of Anemia in Multiple Myeloma , 2003, International journal of hematology.

[20]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[21]  A. Motulsky.  Frequency of sickling disorders in U.S. blacks. , 1973, The New England journal of medicine.

[22]  J. Barnholtz-Sloan,et al.  Survival analysis of distant prostate cancer by decade (1973–1997) in the Detroit Metropolitan Surveillance, Epidemiology and End Results (SEER) Program Registry: has outcome improved? (United States) , 2003, Cancer Causes & Control.

[23]  L. Diehl,et al.  Leukopenia, neutropenia, and reduced hemoglobin levels in healthy American blacks. , 1991, Archives of internal medicine.

[24]  I. Thompson,et al.  Association of African-American ethnic background with survival in men with metastatic prostate cancer. , 2001, Journal of the National Cancer Institute.

[25]  S. George,et al.  Impact of race on survival in men with metastatic hormone-refractory prostate cancer. , 2004, Urology.

[26]  M. Scholz,et al.  Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. , 1997, British journal of urology.

[27]  John T. Wei,et al.  Racial differences in serum prostate‐specific antigen (PSA) doubling time, histopathological variables and long‐term PSA recurrence between African‐American and white American men undergoing radical prostatectomy for clinically localized prostate cancer , 2005, BJU international.

[28]  M. Streitwieser,et al.  Explaining Racial Differences , 1983 .

[29]  C. Mitsiades,et al.  Endocrine/paracrine/autocrine survival factor activity of bone microenvironment participates in the development of androgen ablation and chemotherapy refractoriness of prostate cancer metastasis in skeleton. , 2003, Endocrine-related cancer.

[30]  Y. Oshika,et al.  P-glycoprotein-mediated acquired multidrug resistance of human lung cancer cells in vivo. , 1996, British Journal of Cancer.

[31]  A. Fyles,et al.  Intratumoral sickling in a patient with cervix cancer and sickle trait: effect on blood flow and oxygenation. , 2001, Gynecologic oncology.

[32]  S. Gillen,et al.  Proliferation of prostate cancer cells and activity of neutral endopeptidase is regulated by bombesin and IL‐1β with IL‐1β acting as a modulator of cellular differentiation , 2004, The Prostate.

[33]  A. Renshaw,et al.  Impact of race on prostate-specific antigen outcome after radical prostatectomy for clinically localized adenocarcinoma of the prostate. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Carol West,et al.  Hematologic differences between African-Americans and whites: the roles of iron deficiency and alpha-thalassemia on hemoglobin levels and mean corpuscular volume. , 2005, Blood.

[35]  P. Lane.  Sickle cell disease. , 1996, Pediatric clinics of North America.

[36]  Alicia Samuels,et al.  Cancer Statistics, 2003 , 2003, CA: a cancer journal for clinicians.

[37]  C. Graham,et al.  Hypoxia induced resistance to doxorubicin in prostate cancer cells is inhibited by low concentrations of glyceryl trinitrate. , 2003, The Journal of urology.

[38]  J. Simons,et al.  Interleukin-6: a candidate mediator of human prostate cancer morbidity. , 1995, Urology.

[39]  R A Stephenson,et al.  Racial and ethnic differences in advanced-stage prostate cancer: the Prostate Cancer Outcomes Study. , 2001, Journal of the National Cancer Institute.

[40]  A. Costello,et al.  Interleukin‐6: minor player or starring role in the development of hormone‐refractory prostate cancer? , 2003, BJU international.

[41]  I. Thompson,et al.  Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. , 1998, The New England journal of medicine.

[42]  A. Renshaw,et al.  Initial decline in hemoglobin during neoadjuvant hormonal therapy predicts for early prostate specific antigen failure following radiation and hormonal therapy for patients with intermediate and high‐risk prostate cancer , 2002, Cancer.